Searchable abstracts of presentations at key conferences in endocrinology

ea0051cme6 | CME Training Day Abstracts | BSPED2017

Precocious puberty and its variants

Butler Gary

Precocious pubertal development is generally defined as the clinical manifestation of secondary sex characteristics above the 99.6th centile for age. In the UK this corresponds to 8 years in girls and 9 years in boys. The UK growth charts divide at these ages to remind us that a child who plots on the left sided panel and who has pubertal signs is precocious and warrants medical review. The vertical puberty lines have reminders of precocity (and delay). Stage lines on the RCPC...

ea0036oc3.9 | Oral Communications 3 | BSPED2014

Physiological dose reverse rhythm testosterone treatment abolishes the development of permanent gynaecomastia in adolescents with 47,XXY Klinefelter syndrome

Butler Gary

Introduction: Gynaecomastia (GM) is common in boys with Klinefelter syndrome (KS) during adolescence. It develops due to the relatively higher diurnal oestradiol–testosterone ratio in early to mid puberty. The physiological mid-late pubertal rise in testosterone causes the GM to disappear in chromosomally normal boys, but it persists in boys with KS if this rise in testosterone is blunted.Aim: As a previous longitudinal RCT of testosterone in boys w...

ea0027oc6.2 | Oral Communications (Endocrine Nurse Session) | BSPED2011

An analysis of the clinical and cost effectiveness of GH replacement therapy before and during puberty: should we increase the dose?

Howard Sasha , Butler Gary

Background: We aim to investigate the influence of GH on pubertal growth in children receiving GH replacement therapy for GH deficiency.Methods: We analyse a large dataset of children (n=236) with GH deficiency from the international KIGS database. We examine the relationship between pubertal growth and treatment with GH replacement therapy using linear regression and repeated measures analysis, and the incremental cost benefit of increasing doses...

ea0078p32 | Gonadal, DSD and Reproduction | BSPED2021

Using SITAR analysis to explore the impact of gonadotropin-releasing hormone analogues on the pubertal growth spurt in adolescents with gender dysphoria

Stack Annie , Butler Gary , Cole Tim

Gonadotropin-releasing hormone analogues (GnRHa) are prescribed to adolescents with gender dysphoria under age 15 who have reached Tanner stage 2/3 to prevent progression through puberty and allow them time to consider their gender identity. The possible effects of the therapy on the pubertal growth spurt are poorly understood. A height more congruent with their identified gender is desired by transgender individuals, thus it is crucial that they are fully informed of its pote...

ea0036P49 | (1) | BSPED2014

Pubertal gynaecomastia: when is reverse rhythm testosterone treatment in adolescent boys with delayed puberty effective?

Scolamiero Laura , Davie Samantha , Butler Gary

Introduction: Gynaecomastia (GM) is a major contributor to psychological morbidity in adolescent boys, yet there is a lack of evidence for effective treatment. It is known to develop due to the relatively higher diurnal oestradiol–testosterone ratio in early to mid puberty.Aims: We retrospectively looked to identify possible criteria for the selection of patients to predict optimal management of GM. We also examined the effect on the persistence of ...

ea0058oc8.2 | Oral Communications 8 | BSPED2018

The effect of GnRHa treatment on bone density in young adolescents with gender dysphoria: findings from a large national cohort

Joseph Tobin , Ting Joanna , Butler Gary

Background/Aims: More young people with gender dysphoria are undergoing hormonal intervention with GnRHa treatment. The impact on bone density is not known in the very young transgender adolescents, with guidelines mentioning that Bone Mineral Density (BMD) should be monitored without a suggestion on how. This study aimed to investigate whether there were any changes in BMD or Bone Mineral Apparent Density (BMAD) whilst on GnRHa therapy.Methods: A retros...

ea0066oc4.1 | Oral Communications 4 | BSPED2019

Mortality after childhood growth hormone treatment in the UK – the SAGhE study

Cooke Rosie , Swerdlow Anthony , Clayton Peter , Tollerfield Sally , Butler Gary

Background: Recombinant human growth hormone (r-hGH) has been used for more than 30 years and indications for r-hGH have multiplied worldwide. There has been concern that it might raise mortality, but published data are limited.Methods: The cohort comprised of 3902 UK patients over 18 years of age in 2009, treated with childhood r-hGH at all the major UK growth centres. The total European cohort was 24 232 from eight countries (including the UK), with > ...

ea0039ep71 | Gonadal, DSD and reproduction | BSPED2015

Standard GnRH analogue doses do not adequately suppress puberty in adolescent patients

Lam Francis , Besser Rachel , Goedhart Claire , Brain Caroline , Butler Gary

Introduction: Adolescents with persistent gender dysphoria (GD) receive GnRH analogues to achieve pubertal arrest. It is unclear whether this is adequate to achieve biochemical suppression of gonadotrophin (LH, FSH) and sex hormone production.Methods: Gonadotrophins, testosterone and oestradiol were measured in GD patients (15–18 years) before and after monthly Gonapeptyl treatment (3.75 mg i.m.). Patients administered other analogues and/or cross-s...

ea0095p102 | Diabetes 3 | BSPED2023

Prohormone convertase 1/3 deficiency can be associated with diabetes mellitus in childhood

Varughese Rachel , Howard Sasha , Butler Gary , Dattani Mehul

Prohormone convertase 1/3 (PC1/3) deficiency is rare, caused by homozygous or compound heterozygous mutations in the PCSK1 gene. PCSK1 encodes a serine protease important in cleavage of several proneuropeptides and prohormones. Despite a variety of known endocrine associations, paediatric diabetes mellitus is rare, described only once before. Previous understanding was that biological activity of elevated proinsulin (<5% of the activity of insulin) confers protection from ...